Helixgate

Helixgate

Uncategorized

Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies

The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.

Read More

Published

on

The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

European regulators greenlight Fractyl Health’s clinical test of GLP-1 gene therapy

Published

on

Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to become …

Continue Reading

Uncategorized

CSL sinks to nine-year low on revenue warning, $5B write-down

CSL sinks to nine-year low on revenue warning, $5B write-down

Published

on

CSL’s stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge.

The …​ ​Read More

Continue Reading

Uncategorized

Opinion: AI doctors should be licensed. Here’s a framework to do that

Late last month, Utah’s Medical Licensing Board called for the immediate suspension of the state’s pilot program with the AI company Doctronic. The program lets a chatbot evaluate patients and recommend prescription renewals for nearly 200 chronic condition drugs, with the state planning to phase out physician review of each case.

The board said that it only learned about the pilot after it had launched. Its warning was blunt: proceeding without proper clinical oversight “potentially places Utah citizens at risk.”

Read the rest…

Read More

Published

on

Late last month, Utah’s Medical Licensing Board called for the immediate suspension of the state’s pilot program with the AI company Doctronic. The program lets a chatbot evaluate patients and recommend prescription renewals for nearly 200 chronic condition drugs, with the state planning to phase out physician review of each case.

The board said that it only learned about the pilot after it had launched. Its warning was blunt: proceeding without proper clinical oversight “potentially places Utah citizens at risk.”

Read the rest…

Read More

Continue Reading
Advertisement

Trending